Hepatitis B vaccination for patients with chronic renal failure

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2004, Pages

  Schroth, Robert J ^a   Hitchon, Carol A ^a   Uhanova, Julia ^b   Noreddin, Ayman M ^c   Taback, Shayne P ^a   Moffatt, Michael ^d   Zacharias, James M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b John Buhler Research Centre   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEPATITIS B; HUMAN; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS;

EID: 16544375385     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003775.pub2     Document Type: Review

References (54)

1. Crosnier J. Hepatitis B in haemodialysis: vaccination against HBs antigen. Proceedings of the European Dialysis and Transplantation Association. European Dialysis and Transplant Association. 1981; Vol. 18:231-40.
2. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1981;1(8224):797-800.
3. Degos F, Courouce AM, Vitviski L, Lacour B, Crosnier J. Incidence of hepatitis during a placebo controlled study of vaccine against hepatitis B virus. Liver 1982;3 Pt 2(2):317.
4. Desmyter J, Colaert J, De Groote G, Reynders M, Reerink-Brongers EE, Leli PN, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983;2(8363):1323-8.
5. El-Reshaid K, Al-Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 1994;12(3):223-38.
6. Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. Journal of Hepatology 1986;3(2):190-5.
7. Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. Journal of Hepatology 1986;3(2):190-5.
8. Jungers P, Chauveau P, Courouce AM, Abbassi A, Devillier P, Marie FN, et al. [Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]. La Presse Medicale 1994;23(6):277-80.
9. Jungers P, Chauveau P, Courouce AM, Devillier P, Excler JL, Bailleux F, et al. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. The Journal of Infectious Diseases 1994;169(2):399-402.
10. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. The Journal of Infectious Diseases 1988;157(2):332-7.
11. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. The Journal of infectious diseases 1988;157(2):332-7.
12. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. The New England Journal of Medicine 1984;311(8):496-501.
13. Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgraduate Medical Journal 1987;63 Suppl2:169-77.
14. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - Eurpoean Renal Association 1996;11(1):191-3.
15. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation 2000;36(5):976-82.
16. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994;344(8926):856-7.
17. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 1998;32(6):1041-5.
18. Vincent L, John GT, Abraham P, Jacob CK. An intradermal vaccine protocol against hepatitis B in a haemodialysis population. The National Medical Journal of India 1998;11(1):48.
19. Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. The International Journal of Artificial Organs 1999;22(11):739-43.
20. Alexander D, Peacock E, Curry G, Jacob G. Immunizing the ESRD patient population: providers face challenges. Nephrology News & Issues 1998;12(10):42-4;45-6;66.
21. Center for Disease Control. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report: Recommendations and Reports/Centers for Disease Control. Vol. 50 (RR-5), Altanta, Georgia: CDC, 2001:1-43.
22. Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, et al. Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proceedings of the National Academy of Sciences of the United States of America 1986;83(19):7457-61. [MEDLINE: PMID: 3094009]
23. Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B. Immune deficiency of the uremic patient. Advances in nephrology from the Necker Hospital 1990;19:259-74. [MEDLINE: PMID: 2105582]
24. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4. 2001. Oxfrod: Update Software. Updated quarterly.
25. Moher D, Schulz KF, Altman DG for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. www.consort-statement.org (accessed 21 November 2002).
26. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vaccine 1993;11(12):1229-32.
27. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Statistics in Medicine 2000;19(13):1707-28.
28. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. American Journal of Nephrology 2000;20(1):1-11.
29. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Novel evidence on hepatitis B virus infection in dialysis. The International Journal of Artificial Organs 2001;24(1):8-16.
30. Feuerhake A, Muller R, Lauchart W, Pichlmayr R, Schmidt FW. HBV - vaccination in recipients of kidney allografts. Vaccine 1984;2(4):255-6. [MEDLINE: PMID: 6241770]
31. Fivush BA, Neu AM. Immunization guidelines for pediatric renal disease. Seminars in Nephrology 1998;18(3):256-63.
32. Geerlings W, Tufveson G, Brunner FP, Ehrich JH, Fassbinder W, Landais P, et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrology, Dialysis, Tranpslantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 1991;6 Suppl4:5-29.
33. Girndt M, Kohler H. Hepatitis B virus infection in hemodialysis patients. Seminars in Nephrology 2002;22(4):340-50. [PMID 12118399]
34. Huang CC. Hepatitis in patients with end-stage renal disease. Journal of Gastroenterology and Hepatology 1997;12(9-10):S236-41.
35. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
36. Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M. Vaccines for preventing hepatitis B in health-care workers. Cochrane Library 2000, Issue 1.
37. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clinical Pharmacokinetics 1992;22(6):434-46.
38. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42-6.
39. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
40. Lefebure AF. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993;11(4):397-9.
41. MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. American Journal of Public Health 2001;91(6):965-71.
42. Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet 1998;352(9128):609-13.
43. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet 1999;354(9193):1896-900.
44. Petrosillo N, Puro V, Ippolito G. Prevalence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among dialysis patients. The Italian Multicentric Study on Nosocomial and Occupational Risk of Blood-Borne Infections in Dialysis. Nephron 1993;64(4):636-9. [MEDLINE: PMID: 8366992]
45. Popper H, Schaffner F. Progress in liver diseases. Vol. 9, Toronto: W.B. Saunders Company, 1990.
46. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Seminars in Dialysis 2000;13(2):101-7.
47. Revillard JP. Immunologic alterations in chronic renal insufficiency. Advances in Nephrology from the Necker Hospital 1979;8:365-82. [MEDLINE: PMID: 115248]
48. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
49. Specter SC. Hepatitis B vaccines. In: Specter SC editor(s). Viral Hepatitis: Diagnosis, Therapy, and Prevention. Totowa, NJ: Humana Press, 1999:377-91. [ISBN 0-89603-424-0]
50. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO Journal (American Society for Artificial Internal Organs: 1992) 1998;44(1):98-107. [MEDLINE: PMID: 9466509]
51. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. Seminars in Dialysis 2000;13(2):75-85.
52. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996;38 Suppl 2:S48-55.
53. Walker A. Meta-style and expert review. Lancet 1999;354(9193):1834-5.
54. Zannolli R, Morgese G. Hepatitis B vaccine: current issues. The Annals of Pharmacotherapy 1997;31(9):1059-67.